Welcome to our dedicated page for Jaguar Health news (Ticker: JAGX), a resource for investors and traders seeking the latest updates and insights on Jaguar Health stock.
Jaguar Health, Inc. (NASDAQ: JAGX) news covers a commercial-stage pharmaceuticals company focused on plant-based prescription medicines for gastrointestinal distress in humans and animals. The company’s updates frequently highlight progress across its crofelemer programs, regulatory interactions, and partnerships.
Investors following JAGX news can expect coverage of developments related to Mytesi, Napo Pharmaceuticals’ FDA-approved crofelemer product for noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy, as well as Jaguar’s broader intestinal failure program targeting rare disorders such as short bowel syndrome with intestinal failure (SBS-IF) and microvillus inclusion disease (MVID). News items often describe clinical trial milestones, proof-of-concept data on reductions in parenteral support, and discussions with regulators about potential expedited approval pathways for ultrarare pediatric indications.
On the animal health side, Jaguar news includes information about Canalevia-CA1, the company’s conditionally approved crofelemer-based prescription drug for chemotherapy-induced diarrhea in dogs, along with regulatory grants, conditional approval renewals, and studies designed to support full approval. Updates may also address efforts to obtain guidance from the European Medicines Agency for Canalevia in general diarrhea in dogs.
Corporate and capital markets announcements are another key component of JAGX news. These can include securities purchase agreements, royalty interest amendments, PIPE financings, preferred stock exchanges, and at-the-market offering amendments, as disclosed in Form 8-K filings. Conference presentations, investor summit appearances, and summaries of stockholder meeting results also appear in the company’s news flow.
For investors and observers, the Jaguar Health news page provides a centralized view of clinical, regulatory, commercial, and financing developments that shape the company’s strategy in plant-based gastrointestinal therapeutics for both human and veterinary medicine.
Jaguar Health (NASDAQ:JAGX) has announced a time change for its upcoming investor webcast on August 13, 2021, now scheduled for 8:00 AM Eastern Time.
The company focuses on developing plant-based medications aimed at treating gastrointestinal issues, particularly chronic diarrhea in patients with HIV/AIDS. Their product, Mytesi, is FDA approved for this purpose.
Jaguar will file its Q2 2021 10-Q on the same day as the webcast.
Jaguar Health (NASDAQ:JAGX) announced an investor webcast scheduled for August 13, 2021, at 8:30 AM ET to discuss Q2 financials and company updates. Additionally, in recognition of African Traditional Medicine Day on August 31st, Jaguar is launching an educational awareness contest to honor Indigenous healers. Participants can enter the contest for free, with entries due by 9:00 AM ET on August 31, 2021. The winner will receive a signed painting by Anthony J. Conte. For more details, visit Jaguar's official website.
Jaguar Health (NASDAQ:JAGX) announced the adjournment of its Annual Meeting of Stockholders to September 3, 2021, due to insufficient quorum. Over 75% of votes cast supported proposals 2, 3, 4, and 6. Only an additional 0.84% of eligible stock needs to vote for quorum to be achieved. The company emphasized the importance of shareholder participation, which has been costly and distracting. Stockholders can vote online or through their brokers. No changes were made to the proposals, and the record date remains April 12, 2021.
Jaguar Health (NASDAQ:JAGX) announced an upcoming investor webcast featuring CEO Lisa Conte on July 29, 2021, at 8:30 AM ET. The event aims to provide updates on Jaguar and its subsidiaries, including Napo Pharmaceuticals and Napo EU S.p.A. The recent financing closure by Dragon SPAC for approximately €8.83 million underscores Jaguar's focus on expanding its plant-based gastrointestinal medicines. The company’s Mytesi product, approved by the U.S. FDA, offers symptomatic relief for adults with HIV/AIDS experiencing noninfectious diarrhea.
Jaguar Health, Inc. (NASDAQ:JAGX) announces an upcoming investor webcast featuring an interview with CEO Lisa Conte on July 29, 2021, at 8:30 AM ET. The session will cover business updates for Jaguar and its subsidiaries, including Napo Pharmaceuticals. Recently, Dragon SPAC S.p.A. completed financing for approximately €8.83 million. Jaguar focuses on developing non-opioid, plant-based medicines for gastrointestinal issues. The FDA-approved product Mytesi® provides symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.
Jaguar Health (NASDAQ:JAGX) announced the grant of nonstatutory stock options and restricted stock units (RSUs) to two new employees effective July 15, 2021. Each employee received options for up to 8,000 shares at an exercise price of $1.41 per share, vested over three years. Additionally, 4,000 RSUs were granted to each employee, vesting equally over the same period. These grants were approved by the Compensation Committee as an inducement for employment, contingent on continued service with the company.
Napo EU, a target of Dragon SPAC, aims to develop crofelemer to treat short bowel syndrome (SBS), having received orphan-drug designation from the US FDA. The merger of Napo EU and Dragon SPAC is anticipated to finalize within 80 days, with potential license and milestone fees up to $12.5 million. Recent financing closed with €8.83 million (approx. $10.8 million) from Jaguar Health, Inc. (NASDAQ:JAGX). The global SBS market is projected to grow from $568 million in 2019 to $4.6 billion by 2027.
Jaguar Health (NASDAQ:JAGX) announced the completion of the Phase 2 HALT-D study, investigating Mytesi® (crofelemer) for diarrhea relief in HER2 positive breast cancer patients undergoing chemotherapy. Sponsored by Georgetown University and funded by Genentech, results have been submitted for presentation at the San Antonio Breast Cancer Symposium in December 2021. The study aims to address common chemotherapy-related diarrhea, which can hinder treatment adherence and patient outcomes. Jaguar looks forward to potential publication of these results, separate from the ongoing Phase 3 trial of crofelemer.
Jaguar Health, Inc. (NASDAQ:JAGX) has adjourned its Annual Meeting of Stockholders for the third time due to insufficient quorum. Over 74% of votes cast favor Proposals 2, 3, 4, and 6. The meeting will reconvene on August 6, 2021, at 8:30 AM PST to encourage more participation. As of April 12, 2021, stockholders are reminded to vote if they haven't done so. The company emphasizes that approximately 2.9% of eligible stock must vote to reach quorum. The proposals remain unchanged, and voting options are provided for stockholders.
Jaguar Health (NASDAQ:JAGX) will join the Russell Microcap Index effective June 28, 2021, enhancing its visibility and potentially broadening its institutional shareholder base. The inclusion in this index reflects Jaguar's market capitalization and growth attributes, which can attract investment managers looking for benchmarked stocks. This milestone aligns with the company's ongoing efforts to expand access to crofelemer, its plant-based product approved for treating noninfectious diarrhea in adults with HIV/AIDS.